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Rett syndrome (RTT) is caused by loss-of-function mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2). Although
MeCP2 is thought to act as a transcriptional repressor of brain-derived neurotrophic factor (BDNF),Mecp2 null mice, which develop an
RTT-like phenotype, exhibit progressive deficits in BDNF expression. These deficits are particularly significant in the brainstem and
nodose cranial sensory ganglia (NGs), structures critical for cardiorespiratory homeostasis, andmay be linked to the severe respiratory
abnormalities characteristic of RTT. Therefore, the present study usedMecp2 null mice to further define the role of MeCP2 in regulation
of BDNF expression and neural function, focusing on NG neurons and respiratory control. We find that mutant neurons express signif-
icantly lower levels of BDNF than wild-type cells in vitro, as in vivo, under both depolarizing and nondepolarizing conditions. However,
BDNF levels in mutant NG cells can be increased by chronic depolarization in vitro or by treatment ofMecp2 null mice with CX546, an
ampakine drug that facilitates activation of glutamatergic AMPA receptors. Ampakine-treated Mecp2 null mice also exhibit marked
functional improvement, characterized by restoration of normal breathing frequency andminute volume. These data demonstrate that
BDNF expression remains plastic inMecp2 nullmice and raise the possibility that ampakine compounds could be of therapeutic value in
the treatment of RTT.
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Introduction
Rett syndrome (RTT) is an X-linked neurodevelopmental disor-
der caused by mutations in the methyl-CpG-binding protein 2
gene (MECP2) (Amir et al., 1999). Six to 18 months after birth,
RTT patients begin a neurological decline characterized by re-
gression of acquired skills, behavioral disturbances with autistic
features (Hagberg et al., 1983), motor stereotypies, seizures, au-
tonomic dysfunction, and severely disordered breathing (Shah-
bazian and Zoghbi, 2002). Respiratory abnormalities in RTT in-
clude alternating periods of hyperventilation and breath holds
and forced and apneustic breathing (Weese-Mayer et al., 2006,
and references therein) and may contribute to up to 26% of
deaths in RTT (Kerr et al., 1997). The primary cause of these
breathing alterations is unknown, and current hypotheses in-
clude cortical dysfunction (Elian and Rudolf, 1991; Marcus et al.,
1994), brainstem immaturity (Julu et al., 2001), decreased nor-
adrenergic transmission in ponto-medullary respiratory net-
works (Viemari et al., 2005), and hyperexcitability in pontine and
vagal afferent pathways (Stettner et al., 2007). There is no treat-
ment currently available for respiratory dysfunction in RTT.
Recent studies suggest that alterations in brain-derived neu-
rotrophic factor (BDNF) signaling contribute to RTTpathophys-
iology. For example,Mecp2 null mice exhibit progressive deficits
in BDNF levels after birth (Chang et al., 2006; Wang et al., 2006),
and genetic restoration of BDNF in the forebrain improves so-
matomotor function and extends lifespan (Chang et al., 2006).
Moreover, neural structures important for cardiorespiratory
control, including the nodose cranial sensory ganglia (NGs) and
brainstem, exhibit the earliest and most significant known defi-
cits in BDNF expression in theMecp2 null mouse brain (Wang et
al., 2006). Because BDNF is required for the development of NG
and brainstem respiratory neurons, as well as breathing (Katz,
2005), we hypothesize that BDNF deficits contribute to the RTT-
like respiratory phenotype ofMecp2 null mice.
The fact thatMecp2nullmice exhibit decreased BDNF expres-
sion contrasts with the prevailing view thatMecp2 is a transcrip-
tional repressor of Bdnf (Chen et al., 2003). Onemodel proposed
to explain this apparent discrepancy is that decreased neuronal
activity inMecp2nullmutants (Dani et al., 2005) reduces activity-
dependent BDNF expression, thereby masking any effect of de-
repression (Chang et al., 2006). To test this hypothesis, we exam-
ined BDNF expression in NG neurons cultured under
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depolarizing andnondepolarizing conditions.Because theNGcom-
prises a single neuronal cell type (sensory neurons) and exhibits the
Mecp2null BDNFphenotype in vitro as in vivo (Wang et al., 2006), it
provides a simple model for exploring mechanisms that underlie
BDNF regulation byMeCP2.Our data indicate thatMecp2null cells
exhibit significantly lower levels of BDNF expression thanwild type,
under bothdepolarizing andnondepolarizing conditions.However,
BDNF levels in mutant cells can be elevated to wild-type resting
levels by depolarizing stimuli in vitro. Similarly, we find that treat-
ment of Mecp2 null mice with the ampakine drug 1-(1,4-
benzodioxan-6-yl-carbonyl)piperidine (CX546), which enhances
activationofglutamatergicAMPAreceptors (Nagarajanet al., 2001),
elevates NG BDNF levels in vivo. Moreover, ampakine treatment
significantly improves respiratory function in Mecp2 null mice,
suggesting that this class of compounds may be of therapeutic
value in RTT.
Materials andMethods
Animals. Mecp2tm1–1Jae mice (Chen et al., 2001), developed by Dr. R.
Jaenisch (Whitehead Institute, Massachusetts Institute of Technology,
Cambridge, MA) and obtained from the Mutant Mouse Regional Re-
source Center (University of California Davis, Davis, CA), were main-
tained on a mixed background (129Sv, C57BL/6, BALB/c). Male Mecp2
nulls (Mecp2/y) were generated by crossing heterozygousMecp2tm1–1Jae
knock-out females with Mecp2tm1–1Jae wild-type males (Mecp2/y). All
experimental procedures were approved by the Institutional Animal
Care and Use Committee at Case Western Reserve University.
Cell cultures.Wild-type andMecp2 null mice were killed with CO2 on
postnatal day 35 (P35). The NGs were removed, digested in 0.1% colla-
genase (Sigma, St. Louis, MO) in Earle’s balanced salt solution (Invitro-
gen, SanDiego,CA) for 70min at 37°C, triturated in culturemedium(see
below) containing 0.15%BSA, and plated at a density of one NG per well
into 96-well flat-bottom ELISA plates coated with poly-D-lysine. Cul-
tureswere grown for 3 d inDMEM/F-12medium supplementedwith 5%
fetal bovine serum (Invitrogen) and 1% penicillin–streptomycin–neo-
mycin, with or without 40mM potassium chloride (KCl) or 1.5M tetro-
dotoxin (TTX).
Ampakine treatment. Beginning on P25, wild-type and Mecp2 null
littermates were acclimatized to the injection protocol to reduce stress,
first by handling for 10min/d for 3 d, followed by saline injections (0.9%
NaCl, i.p., b.i.d.) at 8:00 A.M. and 8:00 P.M. for an additional 3 d. Sub-
sequently, mice were assigned either to drug treatment (40mg/kg CX546
in 16.5% 2-hydroxypropyl--cyclodextrin, i.p., b.i.d.) or vehicle injec-
tions (cyclodextrin alone). On the day of their last injection, mice were
trained in the plethysmograph recording chamber for 1 h. Eighteen to
24 h after their last injection, on P35, mice were returned to the chamber
for recording of respiratory activity.
Plethysmography.Breathingwas recorded in unrestrainedmice using a
whole-body flow plethysmograph (Buxco II; Buxco Research Systems,
Wilmington, NC) in which a constant bias flow supply connected to the
animal recording chamber ensured continuous inflow of fresh air (1
L/min). Ambient temperature was maintained between 23 and 25°C.
Breathing traces were analyzed using Biosystem XA software (Buxco
Research Systems). After the recording sessions, mice were euthanized
with CO2 and tissue was processed for BDNF immunoassay.
BDNF reverse transcription-PCR. Total RNA was isolated from intact
P35 NG using the RNeasy Mini kit (Qiagen, Valencia, CA). For each
sample, 500 ng of total RNA was digested with DNase I (Invitrogen,
Carlsbad, CA) and reverse transcribed by oligodT priming using Super-
ScriptIII (Invitrogen). The amount of each Bdnf transcript present in the
sample was measured by quantitative real-time PCR (qRT-PCR) using
SYBR Green detection (Applied Biosystems, Foster City, CA). Bdnf
mRNA levels were normalized to -tubulin IIImRNA levels to adjust for
small differences in input RNA. The following primers were used for qRT-
PCR: Bdnf exon 8 (coding exon), forward (F) 5-gatgccgcaaacatgtctatga-3
and reverse (R) 5-taatactgtcacacacgctcagctc-3; Bdnf exon 1, F 5-
cactgagcaaagccgaacttctc-3 and R 5-tcacctggtggaacattgtggc-3; Bdnf exon 2,
F 5-agcggtgtaggctggaatagactc-3 and R 5-ggtggaacttctttgcggcttac-3; Bdnf
exon 4, F 5-cgccatgcaatttccactatcaataatttaac-3 and R 5-cgccttcatgcaac-
cgaagtatg-3; Bdnf exon 5, F 5-gatccgagagctttgtgtggac-3 and R 5-gccttcat-
gcaaccgaagtatg-3; -tubulin III, F 5-cgacaatgaagccctctacgac-3 and R 5-
atggtggcagacacaaggtggttg-3.
BDNF immunoassay. BDNF protein levels in intact NGs or in cultured
NG cells were measured by ELISA using the BDNF Emax Immunoassay
System (Promega,Madison,WI). Protein extracts from one intact NG or
from an equivalent number of cultured cells were used for ELISA.
MeCP2 and -tubulin III double staining. Mice were killed with CO2
and perfused with 4% paraformaldehyde, and the head was sectioned at
10mwith a cryostat. Sections were stained with rabbit polyclonal anti-
MeCP2 (Upstate Biotechnology, Lake Placid, NY) and chicken poly-
clonal anti--tubulin III (Aves Labs, Ft. Lauderdale, FL).
Statistical analysis. Differences between wild-type and mutant mice,
and between vehicle-treated and CX546-treated mice, were tested using
an unpaired t test or ANOVA I with Tukey’s multiple comparison post
hoc analysis. A p value0.05was considered statistically significant. Data
are presented as mean SEM.
Results
Bdnf gene expression is reduced inMecp2 null cells in vivo
We previously found that BDNF protein content of peripheral
and CNS tissues is markedly reduced in Mecp2 null mice by 5
weeks of age (Wang et al., 2006; see also Chang et al., 2006). To
determine whether these deficits are reflective of decreased Bdnf
gene expression, we compared Bdnf mRNA levels in wild-type
and mutant animals, using the NG as a model. This analysis re-
vealed that on P35, total BdnfmRNA was reduced by 50% in the
Mecp2 null NG compared with wild-type controls (Fig. 1), paral-
leling the deficit in BDNF protein (Wang et al., 2006). However,
not all Bdnf transcripts were similarly affected. For example, al-
though Bdnf splice variants containing exon 2, 4, or 5 were all
decreased by 50% in mutant tissue compared with wild type,
transcripts containing exon 1 were unchanged. These data indi-
cate thatMeCP2 function is required tomaintain normal levels of
BDNF expression by regulating specific isoforms of BdnfmRNA.
Themarked deficit in BDNF content found in P35Mecp2 null
NGneurons in vivo ismaintained in dissociate cell culture (Wang
et al., 2006), suggesting that it may be a cell-autonomous effect of
MeCP2 loss. However, MeCP2 expression in peripheral neurons
Figure 1. Mecp2 nullmutation is associatedwith decreased expression of specific Bdnf tran-
scripts innodoseneurons.Bdnf transcript levels in intactNG fromwild-typeandMecp2nullmice
were determined using qRT-PCR. The Bdnf gene has a complex structure in which multiple
promoters drive the expressionof differentmRNA isoforms containingalternativenoncoding5
exons spliced toa commondownstreamcodingexon [exon8; nomenclatureof Liu et al. (2006)].
Total Bdnf mRNA levels (Exon 8), as well as transcripts containing exons 2, 4, and 5 were
markedly decreased in mutant NG compared with wild type, whereas transcripts containing
exon 1were expressed at levels that were not significantly different fromwild type. Results are
the mean SEM (n 4). ***p 0.001, ANOVA I with post hoc Tukey’s test.
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has not previously been described. There-
fore, initial studies examined the localiza-
tion of MeCP2 immunoreactivity in the
NG and found robust expression in all
neurons at P0 through P35 (Fig. 2 and data
not shown).
To test the hypothesis that differences in
BDNF content between wild-type and
Mecp2null cells result fromdifferent levelsof
activity (Chang et al., 2006), BDNF levels
were compared in P35 NG neurons from
wild-type andMecp2nullmice grown indis-
sociated culture for 3 d under control (non-
depolarizing) anddepolarizing (40mMKCl)
conditions. Under control conditions, NG
neurons exhibit resting membrane poten-
tials of approximately70 mV and are not
spontaneously active (Schild and Kunze,
1997; Brosenitsch et al., 1998). However, to eliminate any possible
depolarizing influence of voltage-gated sodium channels, some cul-
tures were grown in the presence of 1.5 M TTX [NG neurons also
expressTTX-insensitiveNachannels; however, these activate at sub-
stantially more positive membrane potentials (Schild and Kunze,
1997)]. In both control and TTX-treated cultures,Mecp2 null neu-
rons exhibit 40–50%lessBDNFthanwild-typeneurons (Fig. 3A), as
in vivo, without any change in cell survival (Fig. 3B).
To further test the role of membrane depolarization in the
BDNF phenotype of Mecp2 null neurons, NG cultures were
grown in the absence and presence of a depolarizing concentra-
tion of KCl (40mM). In both wild-type andmutant cultures, KCl
depolarization resulted in a significant increase in BDNF protein
compared with unstimulated controls (Fig. 3C), with no change
in cell survival (Fig. 3D). However, even under depolarizing con-
ditions, mutant cells expressed significantly lower levels of BDNF
than wild-type cells. These data indicate that Mecp2 is required
for normal levels of BDNF expression in NG neurons under both
resting and depolarizing conditions. In addition, these experi-
ments show that chronic depolarization of mutant neurons can
stimulate BDNF protein expression to wild-type resting levels.
This observation is consistent with previous observations show-
ing increased expression of Bdnf exon 4 mRNA in cultured new-
born Mecp2 null cortical cells after KCl treatment (Chen et al.,
2003).
Ampakine stimulation of BDNF expression in vivo
The fact that depolarization of Mecp2 null NG neurons could
increase BDNF expression in vitro raised the possibility that neu-
ronal activation could rescue the BDNF deficit in vivo. To ap-
proach this issue, we examined the effect of an ampakine drug,
CX546, on BDNF protein expression in the NG in intact P35
wild-type andMecp2 null mice. Ampakines are fast-acting mole-
cules that acutely lengthen the duration of AMPA receptor-
mediated inward currents and thereby increase the activity of
neurons that express AMPA receptors (Nagarajan et al., 2001). As
a result, repeated ampakine treatment leads to an increase in
activity-dependent expression of BDNF, in vivo and in vitro (Lau-
terborn et al., 2000, 2003; Rex et al., 2006).
P35 wild-type and Mecp2 null littermates were treated for
3 d with CX546 (40 mg/kg in cyclodextrin, i.p., b.i.d.) or ve-
hicle. Twenty-four hours after the last injection, respiratory
activity was measured (see below), the mice were killed, and
the NG was removed for BDNF ELISA. NG BDNF content in
vehicle-treated Mecp2 null mice was significantly reduced
compared with vehicle-treated wild-type controls, as de-
scribed previously in naive untreated animals (wild type,
170 14 pg BDNF/ml vs mutant, 72 3 pg BDNF/ml; n 6;
p  0.001, ANOVA I). Treatment of wild-type mice with
CX546 had no effect on NG BDNF content. However, treat-
ment ofMecp2 null mice resulted in a significant 42% increase
in BDNF protein content compared with vehicle-treated mu-
tants (wild-type CX546, 167  5 pg BDNF/ml vs mutant,
CX546 114  4 pg BDNF/ml; n  6; p  0.001, ANOVA I).
Ampakine treatment restores wild-type mean respiratory
frequency andminute volume inMecp2tm1–1Jae null mice
NG neurons secrete BDNF in an activity-dependent manner
(Balkowiec and Katz, 2000), and BDNF acutely modulates
glutamatergic transmission at second-order neurons in the
nucleus tractus solitarius (nTS) (Balkowiec et al., 2000), the
primary relay for peripheral afferent input to the brainstem
respiratory rhythm generating network. Therefore, we hy-
pothesize that BDNF deficits in NG neurons contribute to the
Figure 2. MeCP2 protein is expressed in nodose neurons. Left, Double immunostaining for MeCP2 (green) and-tubulin III
(red) in the newbornwild-type (Mecp2/y)mouseNG. nX, Vagal nerve. Right, Highermagnification of the same section shownon
the left, illustrating the concentrationofMeCP2-immunoreactiveprotein inheterochromatin foci. The inset shows that theMeCP2
antibody used in these studies does not produce any specific staining in the NG fromaMecp2 nullmouse (Mecp2/y). The asterisk
represents an anatomical landmark shared by both panels.
Figure 3. BDNF levels are depressed in P35 Mecp2/y NG neurons under resting and dep-
darizing conditions.A,C, Summarydata showing that BDNF content is decreasedby40–50% in
NG cultures fromMecp2nullmutants, regardless of the activity state of the cells [i.e., electrically
silent (A; treatedwithTTX)or chronic depolarization (C, treatedwithKCl)]. Results showthatKCl
treatment can increase the BDNF level in mutant cells as in wild-type controls. B, D, Neuron
survival was unaffected by either TTX (B) or KCl (D). Results are the mean SEM (n 6).
**p 0.01, ANOVA I with post hoc Tukey’s test.
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pathogenesis of respiratory dysfunction in RTT by disrupting
synaptic modulation in nTS.
To examine whether or not ampakine enhancement of BDNF
expression inMecp2 null NG neurons is associated with recovery
of neural function, we compared respiratory activity in wild-type
andmutant mice after treatment with CX546 in vivo as described
above. Respiratory function was monitored by whole-body
plethysmography 18–24 h after the last drug injection as de-
scribed in Materials and Methods. Analysis of naive untreated
wild-type and mutant animals revealed a highly disordered
breathing pattern in the mutants compared with wild-type con-
trols (Fig. 4). The mutant breathing pattern is characterized by a
highly variable frequency (coefficient of variation of breathing
frequency: wild type, 18.8 0.7% vs mutant, 22.0 1.2%; n 6
for wild type and n 7 formutants; p 0.05, unpaired t test) and
occasional long breathing pauses compared with wild types, sim-
ilar to human RTT patients (Julu et al., 2001;Weese-Mayer et al.,
2006) and other models of RTT (Mecp2tm1–1Bird null mice) (Vi-
emari et al., 2005; Stettner et al., 2007). More detailed analysis of
breathing parameters revealed that the phenotype observed in
mutant mice is associated with repetitive episodes of very high
breathing frequency (Fig. 4), resulting in a 23% increase in mean
respiratory frequency compared with wild-type controls ( p 
0.001, unpaired t test; n 6 for wild type and n 7 formutants),
similar to RTT patients (Weese-Mayer et al., 2006). Conse-
quently, the mean value for minute volume/weight (tidal vol-
ume/weight breathing frequency) is also increased in mutants
(Fig. 4) (wild type, 0.97 0.11 ml/min/g vs mutant, 1.38 0.13
ml/min/g; n 6 for wild-types and n 7 for mutants; p 0.05,
unpaired t test). In contrast, there was no significant difference in
tidal volume/weight alone between wild-type and mutant ani-
mals (wild type, 5.4 0.6l/g vsmutant, 6.4 0.5l/g; n 6 for
wild types and n 7 for mutants).
Three-day treatment with CX546 did not significantly affect
breathing frequency, tidal volume/weight, and minute volume/
weight in P35 Mecp2tm1–1Jae wild-type mice (vehicle vs CX546:
frequency, 179 3 vs 177 6 breaths/min; tidal volume/weight,
6.1  0.4 vs 6.4  0.5 l/g; minute volume/weight, 1.09  0.07
ml/min/g vs 1.14 0.09ml/min/g; n 8 for vehicle and n 7 for
CX546). In contrast, ampakine treatment of mutant animals
sharply decreased the episodes of high breathing frequency, lead-
ing to restoration of wild-type mean breathing frequency (Fig.
5A,C) (wild-typeCX546, 177 6 breaths/min vsmutant CX546,
176 8 breaths/min; n 7 for wild types and n 9 formutants)
and minute volume/weight (Fig. 5B,D) (wild-type CX546,
1.14  0.09 ml/min/g vs mutant CX546, 1.13  0.07 ml/min/g;
n 7 for wild types and n 9 for mutants). However, ampakine
treatment did not decrease the higher variability in breathing
frequency characteristic of mutant animals (coefficient of varia-
tion of breathing frequency: wild-type CX546, 18.5  1.2% vs
mutant CX546, 23.4 1.5%; n 7 for wild types and n 9 for
mutants). Tidal volume/weight was not affected in mutants by
ampakine treatment and was similar to wild type (wild-type
CX546 vs mutant CX546, 6.4  0.5 vs 6.5  0.3 l/g; n  7 for
wild types and n 9 for mutants).
Discussion
Our results demonstrate thatMeCP2 is re-
quired for normal levels of BDNF expres-
sion in nodose sensory neurons under
both resting and depolarizing conditions
in vitro. Moreover, chronic depolarization
in vitro, or ampakine treatment in vivo, can
elevate BDNF levels in Mecp2 null cells.
Furthermore, ampakine treatment results
in a restoration of wild-type breathing fre-
quency and minute volume/weight in
Mecp2 null mice.
Previous studies in cultured newborn
cortical neurons indicated that MeCP2 re-
pressesBdnf expression at rest (Chen et al.,
2003) and that release from MeCP2-
mediated repression is required for nor-
mal levels of activity-dependent expres-
sion of BDNF (Martinowich et al., 2003;
Zhou et al., 2006). However, Mecp2 null
mice exhibit deficits in BDNF protein
(Chang et al., 2006; Wang et al., 2006) and
mRNA (present study) in vivo. Moreover,
reduced Bdnf gene expression has recently
been reported in the frontal cortex of RTT
patients (Deng et al., 2007). A proposed
explanation for these discrepancies be-
tween in vivo and in vitro studies is that
Mecp2 null cortical neurons are less active
in vivo than wild-type cells (Dani et al.,
2005), leading to a reduction in activity-
dependent BDNF expression that masks
any effects of BDNF derepression (Chen et
al., 2003; Chang et al., 2006; Sun and Wu,
2006). However, our data indicate that, as
Figure4. Mecp2nullmice exhibit a Rett-like respiratory phenotype at 5weeks of age (P35). Representative plethysmographic
recordings fromwild-type (Mecp2/ y) andMecp2 null (Mecp2/y)mice are shown. Each trace is 10 s quiet breathing in room air.
The bottom graphs are frequency histograms from control (compilation of 9776 breath cycles) and mutant (compilation of 6065
breath cycles) mice showing the higher incidence of fast breaths in mutant mice compared with controls, along with a shift to
higher values of minute volume/weight. BPM, Breaths per minute; MV, minute volume.
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in vivo, Mecp2 null NG neurons grown in
dissociated cell culture express signifi-
cantly less BDNF than wild-type cells and
that this deficit persists under both nonde-
polarizing and depolarizing conditions in
culture. These observations indicate that
reduced activity alone may be insufficient
to explain the BDNF deficit inMecp2 null
neurons. This apparent difference in
BDNF regulation in Mecp2 null mouse
cortical and NG neurons, respectively,
may indicate a role for cell context, includ-
ing cell type and age, in determining the
interaction between these two genes. For
example, it is possible that in P35 NG neu-
rons, unlike newborn cortical neurons
(Chen et al., 2003), MeCP2 indirectly reg-
ulates BDNF expression, perhaps by re-
pressing a gene or genes that, in turn, re-
press BDNF. There are other differences
between the present study and that of
Chen et al. (2003) that may also be impor-
tant, including the fact that Chen et al.
(2003) only looked at regulation of the
exon 4-containing Bdnf transcript and
stimulated their cultures with KCl for 6 h,
compared with 3 d in the present study.
The fact that BDNF expression remains
plastic inMecp2 null NG neurons and can
be increased by depolarizing stimuli in
vitro led us to test whether or not BDNF
levels could be increased in Mecp2 null
mice in vivo by the ampakine drug CX546.
Ampakines are a family of smallmolecules that trigger short-term
increases in the duration of AMPA-mediated inward currents
(Nagarajan et al., 2001). In addition, repeated treatment with
ampakines can increase the efficiency of long-term potentiation
in the hippocampus and facilitate memory processes (Ingvar et
al., 1997; Rex et al., 2006; Wezenberg et al., 2006). These long-
term effects of ampakine treatment result from their ability to
increase Bdnf mRNA and protein expression (Lauterborn et al.,
2000, 2003; Rex et al., 2006).
Our study reveals that chronic treatment with CX546 signifi-
cantly improves respiratory behavior in adult symptomatic
Mecp2 null mice. Indeed, drug treatment significantly decreased
breathing frequency andminute volume/weight, two parameters
that are markedly increased in RTT patients and may contribute
to severe hypocapnic alkalemia and hypoxemia (Southall et al.,
1988). The respiratory improvement was not an acute effect of
ampakine treatment, because CX546 has an extremely short half-
life (1 h) (Hampson et al., 1998; Wezenberg et al., 2006) and
breathing was analyzed 18–24 h after the last drug injection.
Thus, improved breathing is attributable to long-term effects of
the ampakine treatment. Although mechanisms that underlie
improved respiration in ampakine-treated Mecp2 null mice re-
main to be defined, our data are consistent with a role for in-
creased BDNF expression in the NG. NG neurons project cen-
trally to the brainstem nTS, the primary site for afferent input to
the brainstem respiratory rhythm generating network, where
BDNF inhibits glutamatergic excitation of second-order vagal
sensory relay neurons (Balkowiec et al., 2000). In Mecp2 null
mice, BDNF is severely depleted in NG afferents and their pro-
jections to nTS (Wang et al., 2006), and activity of postsynaptic
neurons is increased (D. D. Kline, personal communication)
comparedwithwild-type controls. Thus, we suspect that elevated
respiratory frequency in Mecp2 null mice may result, in part,
from increased excitability in nTS and that ampakine treatment
restores wild-type respiratory frequency by enhancing BDNF
modulation of primary afferent transmission. This possibility is
supported by recent findings that breathing dysfunction in
Mecp2 null mice results from enhanced excitatory (or decreased
inhibitory) neurotransmission affecting both vagal sensory and
brainstem respiratory cell groups. In particular, Stettner et al.
(2007) described hyperexcitability of pontine cell groups in-
volved in the regulation of postinspiratory discharge (Kolliker-
Fuse and lateral parabrachial nuclei) and a loss of desensitization
in vagal afferent control of breathing inMecp2 null mice. It is also
possible that ampakine treatment has direct effects in the brain-
stem as well.
Neuropathological studies in RTT patients and Mecp2 null
mice indicate relatively subtle structural abnormalities, such as
decreased dendritic arbor complexity (Chen et al., 2001; Arm-
strong, 2002; Kishi and Macklis, 2004), that likely reflect disrup-
tions in transynaptic signaling rather than overt neuronal degen-
eration, raising the possibility that functional deficits in RTTmay
be reversible. This possibility has recently been strengthened by
the demonstration that postnatal re-expression of Mecp2 in se-
verely symptomaticMecp2 null mice is associated with symptom
reversal (Guy et al., 2007). Our findings demonstrate that ampa-
kine treatment of symptomaticMecp2 null mice can significantly
improve respiratory function, raising the possibility that this class
of compounds may be of therapeutic value in the treatment of
RTT patients.
Figure 5. Chronic treatment with CX546 restores normal breathing frequency and minute volume/weight in P35Mecp2 null
mice. A, B, Representative histograms of breathing frequency (A) and minute volume/weight (B) from two mutant mice, one
treated with vehicle (9227 breath cycles) and one treated with CX546 (8393 breath cycles), showing that drug treatment (40
mg/kg, b.i.d for 3 d) decreases episodes of high breathing frequency and minute volume/weight. C, D, Summary data for
breathing frequency (C) and minute volume/weight (D) for all animals. Ampakine treatment completely restores wild-type
frequency andminute volume/weight inmutant animals and has no effect in wild types. Results are themean SEM (n 8 for
vehicle-treated wild types; n 7 for CX546-treated wild types; n 8 for vehicle-treated mutants; n 9 for CX546-treated
mutants). *p 0.05; **p 0.01, ANOVA I with post hoc Tukey’s test. BPM, Breaths per minute.
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